Idera Pharmaceuticals Inc. (NASDAQ:IDRA)’s traded shares stood at 0.42 million during the last session, with the company’s beta value hitting 1.82. At the close of trading, the stock’s price was $1.02, to imply an increase of 2.72% or $0.03 in intraday trading. The IDRA share’s 52-week high remains $6.14, putting it -501.96% down since that peak but still an impressive 4.9% since price per share fell to its 52-week low of $0.97. The company has a valuation of $53.77M, with an average of 0.41 million shares in intraday trading volume over the past 10 days and average of 542.96K shares over the past 3 months.
Analysts have given a consensus recommendation of a Hold for Idera Pharmaceuticals Inc. (IDRA), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give IDRA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.17.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) trade information
After registering a 2.72% upside in the last session, Idera Pharmaceuticals Inc. (IDRA) has traded red over the past five days. The stock hit a weekly high of 1.0600 this Friday, 10/08/21, jumping 2.72% in its intraday price action. The 5-day price performance for the stock is -0.97%, and -1.92% over 30 days. With these gigs, the year-to-date price performance is -72.21%. Short interest in Idera Pharmaceuticals Inc. (NASDAQ:IDRA) saw shorts transact 3.7 million shares and set a 3.51 days time to cover.
Analysts on Wall Street suggest a consensus price target of $1.00, implying a decrease of -2.0% to the stock’s current value. The extremes give us $1.00 and $1.00 for target low and target high price respectively. As such, IDRA has been trading 1.96% off suggested target high and 1.96% from its likely low.
Idera Pharmaceuticals Inc. (IDRA) estimates and forecasts
Revenue is forecast to grow 71.20% this quarter before jumping 92.90% for the next one.
Idera Pharmaceuticals Inc. has its next earnings report out between August 02 and August 06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Idera Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA)’s Major holders
Idera Pharmaceuticals Inc. insiders hold 22.62% of total outstanding shares, with institutional holders owning 19.73% of the shares at 25.49% float percentage. In total, 19.73% institutions holds shares in the company, led by Baker Brothers Advisors, LLC. As of Mar 30, 2021, the company held over 2.05 million shares (or 4.09% of shares), all amounting to roughly $2.66 million.
The next major institution holding the largest number of shares is Anson Funds Management LP with 1.71 million shares, or about 3.41% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $2.22 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Idera Pharmaceuticals Inc. (IDRA) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 0.78 million shares. This is just over 1.55% of the total shares, with a market valuation of $1.01 million. Data from the same date shows that the other fund manager holds a little less at 0.44 million, or 0.89% of the shares, all valued at about 0.58 million.